Overview

A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
A Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)
Phase:
Phase 2
Details
Lead Sponsor:
Oramed, Ltd.
Collaborator:
Julius Clinical, The Netherlands
Treatments:
Insulin
Insulin, Globin Zinc